 Fulcrum Therapeutics, Inc. FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the 2020 American Academy of Neurology AAN Science Highlights Virtual Platform. AANs annual meeting was cancelled due to COVID-19 and the virtual platform allows for all accepted oral and poster presentations to be presented. We are pleased by the breadth of losmapimod data selected for presentation, which highlights the progress weve made to develop a treatment for patients with facioscapulohumeral muscular dystrophy FSHD and our approach to treating the root cause of genetically defined rare diseases, said Diego Cadavid, M.D., Fulcrums senior vice president, clinical development. 